Pelthos Therapeutics, Inc. (PTHS)
9.48
+0.18
(+1.94%)
USD |
NYAM |
Nov 06, 10:25
Pelthos Therapeutics Net Income (Quarterly) : -23.42M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -23.42M |
| March 31, 2026 | -25.07M |
| December 31, 2025 | -21.66M |
| September 30, 2025 | -16.24M |
| June 30, 2025 | -3.449M |
| March 31, 2025 | -1.968M |
| September 30, 2024 | -1.695M |
| June 30, 2024 | -1.772M |
| March 31, 2024 | -2.562M |
| Date | Value |
|---|---|
| December 31, 2023 | -4.039M |
| September 30, 2023 | -1.422M |
| June 30, 2023 | -0.9533M |
| March 31, 2023 | -0.9666M |
| December 31, 2022 | -0.7396M |
| September 30, 2022 | -0.5567M |
| June 30, 2022 | -0.3341M |
| March 31, 2022 | -0.3104M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | -61.04M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 15.60M |
| Total Expenses (Quarterly) | 39.02M |
| EPS Diluted (Quarterly) | -6.616 |
| Enterprise Value | 83.13M |
| Gross Profit Margin (Quarterly) | 68.40% |
| Profit Margin (Quarterly) | -150.1% |
| Earnings Yield | -278.0% |
| Normalized Earnings Yield | -213.10 |